Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals Target Price
Analysts' 12-month price predictions for REGN.
Share Price
$521
Average Target Price
$800.75
53.7% upside
53.7% upside4 analysts in the last 4 months
High: $903 | Low: $695
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-06-02 | Morgan StanleyTerence Flynn | $755 | 44.9% upside |  |
| 2025-04-22 | Cantor FitzgeraldCarter Gould | $695 | 33.4% upside | |
| 2025-04-22 | Canaccord GenuityJohn Newman | $850 | 63.1% upside | |
| 2025-03-14 | BMO Capital | $903 | 73.3% upside | |
| 2024-11-01 | BMO CapitalEvan David Seigerman | $1,190 | 128.4% upside | |
| 2024-11-01 | Piper SandlerChristopher Raymond | $1,195 | 129.4% upside | |
| 2024-11-01 | Leerink PartnersAndrew Berens | $880 | 68.9% upside | |
| 2024-10-31 | Evercore ISICory Kasimov | $1,170 | 124.6% upside | |
| 2024-10-24 | Evercore ISICory Kasimov | $1,175 | 125.5% upside | |
| 2024-10-23 | Wells FargoMohit Bansal | $1,050 | 101.5% upside | |
| 2024-09-24 | Truist FinancialThomas Klee | $1,200 | 130.3% upside | |
| 2024-09-24 | Leerink PartnersDavid Risinger | $1,077 | 106.7% upside | |
| 2024-09-24 | Robert W. BairdBrian Skorney | $940 | 80.4% upside | |
| 2024-09-24 | Goldman SachsSalveen Richter | $1,292 | 148% upside | |
| 2024-09-12 | BMO CapitalEvan David Seigerman | $1,300 | 149.5% upside | |
| 2024-09-09 | RBC CapitalBrian Abrahams | $1,282 | 146.1% upside | |
| 2024-08-23 | Raymond JamesChristopher Raymond | $1,242 | 138.4% upside | |
| 2024-08-02 | Bank of America SecuritiesGeoff Meacham | $805 | 54.5% upside | |
| 2024-08-02 | RBC CapitalBrian Abrahams | $1,240 | 138% upside | |
| 2024-07-19 | Raymond JamesChristopher Raymond | $1,166 | 123.8% upside | |
| 2024-07-18 | GuggenheimYatin Suneja | $1,180 | 126.5% upside | |
| 2024-07-12 | UBSTrung Huynh | $1,250 | 139.9% upside | |
| 2024-07-11 | Morgan StanleyTerence Flynn | $1,182 | 126.9% upside | |
| 2024-06-25 | Argus ResearchJasper Hellweg | $1,170 | 124.6% upside | |
| 2024-06-13 | RBC CapitalBrian Abrahams | $1,299 | 149.3% upside | |
| 2024-06-12 | RBC CapitalBrian Abrahams | $1,229 | 135.9% upside | |
| 2024-06-04 | RBC CapitalBrian Abrahams | $1,200 | 130.3% upside | |
| 2024-06-03 | BMO CapitalEvan David Seigerman | $1,082 | 107.7% upside | |
| 2024-05-20 | Raymond JamesChristopher Raymond | $1,000 | 91.9% upside | |
| 2024-05-13 | Evercore ISICory Kasimov | $1,150 | 120.7% upside | |
| 2024-05-03 | RBC CapitalBrian Abrahams | $1,185 | 127.4% upside | |
| 2024-04-12 | JefferiesAkash Tewari | $1,060 | 103.5% upside | |
| 2024-04-11 | RBC CapitalBrian Abrahams | $1,189 | 128.2% upside | |
| 2024-03-13 | Morgan StanleyMatthew Harrison | $1,115 | 114% upside | |
| 2024-01-12 | BMO CapitalBrian Abrahams | $1,076 | 106.5% upside | |
| 2024-01-12 | RBC CapitalBrian Abrahams | $1,076 | 106.5% upside | |
| 2023-03-27 | Leerink PartnersAndrew Berens | $976 | 87.3% upside | |
| 2023-03-24 | JefferiesAkash Tewari | $925 | 77.5% upside | |
| 2023-02-08 | EF Hutton | $853 | 63.7% upside | |
| 2023-02-06 | RBC Capital | $787 | 51.1% upside | |
| 2023-02-06 | Morgan Stanley | $883 | 69.5% upside | |
| 2023-02-06 | Leerink Partners | $834 | 60.1% upside | |
| 2022-11-11 | Guggenheim | $915 | 75.6% upside | |
| 2022-10-03 | Goldman Sachs | $970 | 86.2% upside | |
| 2022-09-16 | Canaccord Genuity | $750 | 44% upside | |
| 2022-09-13 | Piper Sandler | $775 | 48.8% upside | |
| 2022-09-12 | Wells Fargo | $800 | 53.6% upside | |
| 2022-09-09 | Barclays | $815 | 56.4% upside | |
| 2022-09-09 | Morgan StanleyMatthew Harrison | $851 | 63.3% upside | |
| 2022-09-08 | JefferiesAkash Tewari | $675 | 29.6% upside | |